NGM

NGM Biopharmaceuticals, Inc. [NGM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NGM Stock Summary

Top 10 Correlated Stocks

NGM


In the News

05:30 29 Mar 2024 NGM

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

06:31 29 Mar 2024 NGM

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.

10:16 29 Mar 2024 NGM

Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

06:47 29 Mar 2024 NGM

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.59 per share a year ago.

06:46 29 Mar 2024 NGM

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.

09:00 29 Mar 2024 NGM

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.

08:20 29 Mar 2024 NGM

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

08:20 29 Mar 2024 NGM

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

11:22 29 Mar 2024 NGM

After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)

The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

10:59 29 Mar 2024 NGM

3 Best Penny Stocks To Buy Before November According To Insiders

Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NGM Financial details

Company Rating
Sell
Market Cap
129.37M
Income
-139.83M
Revenue
4.42M
Book val./share
1.8
Cash/share
1.78
Dividend
-
Dividend %
-
Employees
138
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.71
Forward P/E
-2.02
PEG
0.47
P/S
4.63
P/B
0.61
P/C
0.88
P/FCF
-0.74
Quick Ratio
7.43
Current Ratio
7.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.69
EPS next Y
-0.78
EPS next Q
-0.35
EPS this Y
-13.07%
EPS next Y
-53.85%
EPS next 5Y
-63.31%
EPS last 5Y
24.86%
Revenue last 5Y
-46.79%
Revenue Q/Q
-71.65%
EPS Q/Q
-5.71%
-
-
-
-
SMA20
-
SMA50
100%
SMA100
100%
Inst Own
52.11%
Inst Trans
0.89%
ROA
-76%
ROE
-70%
ROC
-0.94%
Gross Margin
100%
Oper. Margin
-714%
Profit Margin
-654%
Payout
-
Shs Outstand
83.46M
Shs Float
52.55M
-
-
-
-
Target Price
16.5
52W Range
0.6-4.69
52W High
-
52W Low
-
RSI
55
Rel Volume
0.17
Avg Volume
1.39M
Volume
234.66K
Perf Week
1.61%
Perf Month
5.7%
Perf Quarter
23.05%
Perf Half Y
47.2%
-
-
-
-
Beta
1.261
-
-
Volatility
0.03%, 0.11%
Prev Close
-2.78%
Price
1.575
Change
1.61%

NGM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.061.281.010.690.05
Net income per share
-0.57-1.37-1.48-1.99-1.73
Operating cash flow per share
-0.82-1.22-0.95-1.81-1.6
Free cash flow per share
-0.89-1.25-0.97-1.83-1.62
Cash per share
6.854.314.753.41.78
Book value per share
6.584.094.353.251.8
Tangible book value per share
6.584.094.353.251.8
Share holders equity per share
6.584.094.353.251.8
Interest debt per share
000.140.110
Market cap
930M2.07B1.37B401.35M70.86M
Enterprise value
684.4M1.93B1.22B333.28M12.05M
P/E ratio
-32.63-22.07-11.99-2.52-0.5
Price to sales ratio
8.9823.7517.537.2516.04
POCF ratio
-22.59-24.85-18.64-2.78-0.54
PFCF ratio
-20.82-24.3-18.22-2.74-0.53
P/B Ratio
2.817.414.071.550.48
PTB ratio
2.817.414.071.550.48
EV to sales
6.6122.0715.716.022.73
Enterprise value over EBITDA
-13.87-18.57-10.14-2-0.08
EV to operating cash flow
-16.62-23.09-16.71-2.31-0.09
EV to free cash flow
-15.32-22.58-16.34-2.28-0.09
Earnings yield
-0.03-0.05-0.08-0.4-2.01
Free cash flow yield
-0.05-0.04-0.05-0.36-1.88
Debt to equity
000.030.020
Debt to assets
000.030.020
Net debt to EBITDA
4.981.421.170.410.41
Current ratio
8.947.246.186.047.79
Interest coverage
000-44.760
Income quality
0.960.810.610.890.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.230.310.470.738.57
Research and developement to revenue
1.251.882.083.2725.36
Intangibles to total assets
00000
Capex to operating cash flow
0.080.020.020.010.01
Capex to revenue
-0.03-0.02-0.02-0.03-0.28
Capex to depreciation
-0.46-0.29-0.28-0.46-0.56
Stock based compensation to revenue
0.130.180.340.596.5
Graham number
9.1611.2412.0312.068.36
ROIC
-0.1-0.34-0.32-0.6-0.99
Return on tangible assets
-0.07-0.29-0.28-0.52-0.84
Graham Net
5.943.673.932.871.54
Working capital
315.53M265.84M317.93M241.02M136.36M
Tangible asset value
330.72M280.04M335.65M259.56M148.64M
Net current asset value
305.56M259.43M312.54M241.02M136.21M
Invested capital
000.030.020
Average receivables
4.44M5.82M5.69M6.26M3.82M
Average payables
7.4M9.34M7.45M6.85M5.72M
Average inventory
0.51110.5
Days sales outstanding
18.3526.8823.18504.79
Days payables outstanding
25.4921.51242.41515.6490.06
Days of inventory on hand
00000
Receivables turnover
19.8913.5815.757.376.16
Payables turnover
14.3216.971.510.710.74
Inventory turnover
129.25M163.97M7.9M5.98M0
ROE
-0.09-0.34-0.34-0.61-0.96
Capex per share
-0.07-0.03-0.02-0.02-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.220.030.020.010
Net income per share
-0.42-0.55-0.46-0.35-0.33
Operating cash flow per share
-0.37-0.51-0.49-0.33-0.28
Free cash flow per share
-0.38-0.52-0.49-0.33-0.28
Cash per share
3.322.822.352.011.78
Book value per share
3.172.692.332.051.8
Tangible book value per share
3.172.692.332.051.8
Share holders equity per share
3.172.692.332.051.8
Interest debt per share
0.090.020.030.020
Market cap
410.57M334.59M213.56M88.5M71.13M
Enterprise value
342.5M271.12M163.04M38.4M12.31M
P/E ratio
-2.97-1.85-1.4-0.77-0.64
Price to sales ratio
22.58148.91150.08152.06431.08
POCF ratio
-13.5-8-5.31-3.26-3.1
PFCF ratio
-13.31-7.87-5.29-3.22-3.07
P/B Ratio
1.581.511.110.520.48
PTB ratio
1.581.511.110.520.48
EV to sales
18.84120.66114.5865.9874.62
Enterprise value over EBITDA
-8.94-5.4-4.07-1.26-0.42
EV to operating cash flow
-11.26-6.48-4.05-1.41-0.54
EV to free cash flow
-11.1-6.38-4.04-1.4-0.53
Earnings yield
-0.08-0.13-0.18-0.33-0.39
Free cash flow yield
-0.08-0.13-0.19-0.31-0.33
Debt to equity
0.020.020.010.010
Debt to assets
0.020.020.010.010
Net debt to EBITDA
1.781.261.261.642.02
Current ratio
6.046.47.197.927.79
Interest coverage
-18.8719.71000
Income quality
0.830.881.050.940.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.545.166.7814.948.11
Research and developement to revenue
2.5718.1822.7339.42129.53
Intangibles to total assets
00000
Capex to operating cash flow
0.010.0200.010.01
Capex to revenue
-0.02-0.3-0.07-0.5-1.14
Capex to depreciation
-0.72-1.1-0.19-0.54-0.36
Stock based compensation to revenue
0.483.85.2511.0138.16
Graham number
5.495.774.934.013.67
ROIC
-0.13-0.21-0.19-0.17-0.2
Return on tangible assets
-0.11-0.17-0.17-0.15-0.16
Graham Net
2.82.382.021.741.53
Working capital
241.02M204.63M175.98M154.69M136.36M
Tangible asset value
259.56M220.93M192.12M169.81M148.64M
Net current asset value
241.02M204.63M175.98M154.69M136.21M
Invested capital
0.020.020.010.010
Average receivables
5.98M4.42M996.5K368K29K
Average payables
6.01M10.87M9.57M5.27M3.84M
Average inventory
1749.5K1.5M749.5K0
Days sales outstanding
37.5250.3546.55031.64
Days payables outstanding
682.921.07K470.91844.2518.11
Days of inventory on hand
0120.56120.5600
Receivables turnover
2.41.791.9302.84
Payables turnover
0.130.080.190.110.17
Inventory turnover
1.11M0.750.7500
ROE
-0.13-0.2-0.2-0.17-0.19
Capex per share
-0.01-0.01000

NGM Frequently Asked Questions

What is NGM Biopharmaceuticals, Inc. stock symbol ?

NGM Biopharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol NGM

Is NGM Biopharmaceuticals, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $16.5. The lowest prediction is $4 and the highest is $29

What is NGM stock prediction ?

What is NGM Biopharmaceuticals, Inc. stock quote today ?

NGM Biopharmaceuticals, Inc. stock price is $1.575 today.

Is NGM Biopharmaceuticals, Inc. stock public?

Yes, NGM Biopharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap